Autifony Therapeutics Limited (Autifony), a company spun out from GSK to develop effective treatments for tinnitus and other hearing disorders, has secured a further £8 million to its Series A funding round.
Previously raising £15m to take its lead drug AUT00063 through to clinical proof of concept for age related hearing loss; Autifony will use the additional funding to push a schizophrenia program into the clinic later this year.
As well as working with Autifony, UCL is also a founder shareholder in Autifony, along with GSK, Imperial Innovations and SV Life Sciences.
To find out more please click here.
About Autifony Therapeutics Ltd
Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spin-out from GSK, which retains equity in the company. The Company is focused on the development of high value, novel medicines to treat hearing disorders. It is funded by SV Life Sciences, Imperial Innovations plc, Pfizer Venture Investments, International Biotechnology Trust PLC, and UCL Business plc. Autifony works closely with hearing research experts at University College London’s Ear Institute, Yale University and other academic collaborators around the world to progress its pioneering research.
About UCL Business PLC
UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market.
For further information, please visit: www.uclb.com